Acne vulgaris affects a large proportion of adolescents and young adults and can lead to long-term scarring and psychological distress. Its pathogenesis involves excessive sebum production, bacterial ...

Please provide your email address to receive an email when new articles are posted on . 10.5% of patients treated with isotretinoin experienced mood changes. 88% of patients experienced symptom ...

Explore how environmental and lifestyle exposures influence acne risk and severity, with new insights into prevention read ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Please provide your email address to receive an email when new articles are posted on . Tret-BPO cream may improve adherence and lesions in the treatment of acne vulgaris, according to a literature ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) surged 30% on Monday after unveiling plans to launch a Phase 3 clinical trial of ...

Acne vulgaris is a multifactorial skin disorder marked by inflammatory and non-inflammatory lesions that can cause significant physical and psychological distress. Traditional treatment options, ...

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026First-in-human ...

Acne vulgaris on the back of a healthy 13-year-old boy A dermatologist explores dealing with increasing bacterial resistance and selecting the treatment that minimizes irritation and other skin ...

Acne remains a very common inflammatory dermatosis, which is often associated with significant psychological morbidity. It frequently affects young adults at a time when they are undergoing maximal ...

The approval of Winlevi was based on data from 2 double-blind, vehicle-controlled phase 3 trials in 1440 patients with facial acne vulgaris. Winlevi ® (clascoterone cream 1%) is now available for the ...

A discussion on the benefits of combination drug therapy for adherence. Casey Butrus, PharmD: I know there have been some new therapies, but I wouldn’t say necessarily a lot, that have been FDA ...